FOIA documents: In 2015 Novartis asked U.S. Dept of Commerce to Pressure Colombia Against Compulsory License on Glivec

Posted on by Andrew Goldman

In February 2016, KEI submitted a FOIA to USTR requesting “all correspondence and notes sent internally by the Office of the US Trade Representative as well as with Colombian government officials, other foreign government officials, and non-governmental persons or entities regarding efforts in the government of Colombia to issue compulsory licenses on medical technologies. Continue Reading →

WTO TRIPS Council: Brazil, China, Fiji, India, and South Africa table agenda item on IP and the Public Interest

Posted on by Thiru

On 31 May 2017, the delegations of Brazil, China, Fiji, India, and South Africa tabled a paper to the World Trade Organization’s (WTO) TRIPS Council entitled “Intellectual Property and the Public Interest.” In their communication (IP/C/W/630), the proponents called for a series of discussions at the WTO TRIPS Council on Intellectual Property and the Public Interest. Brazil, China, Fiji, India, and South Africa proposed compulsory licensing as the first theme of IP and the Public Interest discussions at the TRIPS Council meeting in June 2017.

Continue Reading →

2017: PathoVax license on Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines

Posted on by KEI Staff

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On June 5, 2017, KEI provided comments to the NIH/NCI, on a prospective grant of an exclusive license to PathoVax, relating to HPV vaccines. On July 10,… Continue Reading →

WHO donors in 2016 (US, Gates Foundation, UK, GAVI Alliance, Japan): Setting the agenda for global public health?

Posted on by Thiru

In the run up to the 70th World Health Assembly (22 May 2017 – 31 May 2017), the World Health Organization prepared a document (A70/INF./4, 16 May 2017) entitled, Voluntary contributions by fund and by contributor, 2016. Total voluntary contributions to WHO in 2016 amounted to $1,717,219,177 which represented a dip from the 2015 figure of $1,836,970,206.

Here is a non-exhaustive list detailing the sources of voluntary contributions to WHO and the size of their respective contributions in 2016.

Continue Reading →

Uncategorized

2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors Useful for Treating Cancer

Posted on by KEI Staff

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 31, 2017, we sent the following comment to the NIH regarding the proposed exclusive license on certain patents for cancer treatment to GeneXion Oncology. May 31,… Continue Reading →

KEI Statements on World Health Assembly Committee Passage of Cancer Resolution | May 30, 2017

Posted on by KEI Staff

For additional information, contact:

  • James Love (+41.76.413.6854 thru Wed., May 31, 2017, and +1.202.361.3040 thereafter, james.love@keionline.org)
  • Thiru Balasubramaniam (thiru@keionline.org, +41.76.508.0997)

The final text of the resolution (WHA70.12, Cancer prevention and control in the context of an integrated approach) can be found it here: http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_R12-en.pdf

Continue Reading →

Uncategorized